Shots:
- Generic medicines play a pivotal role in offering cost-effective alternatives to high-priced pharmaceuticals. They often serve as a critical lifeline in developing and underdeveloped nations, helping to address both chronic and infectious diseases.
- In 2024, the global generics market was valued at $445.62B, with projections to reach approximately $468.08B in 2025 and ~$728.64B by 2030, growing at a CAGR of 5.04%. Leading the market in 2024, Sandoz generated $10.35B in generic drug revenue, followed by Sun Pharma with $6.26B and Fosun Pharma with $5.6B.
- PharmaShots presents a concise report on the Top 20 Generic Pharma Companies, ranked by their 2024 revenue.
| Rank | Companies | Generic Revenue (2023 $B) | Generic Revenue (2024 $B) | Percent change (%) |
| 1 | Sandoz | 9.64 | 10.35 | 7.36 |
| 2 | Sun Pharma | 5.82 | 6.26 | 7.47 |
| 3 | Fosun Pharma | 5.81 | 5.6 | -3.68 |
| 4 | Viatris | 5.58 | 5.49 | -1.71 |
| 5 | Fresenius Kabi | 4.22 | 3.99 | -5.55 |
| 6 | Aurobindo Pharma | 3.26 | 3.61 | 10.86 |
| 7 | Teva | 3.13 | 3.59 | 14.68 |
| 8 | Dr.Reddy’s | 3.15 | 3.51 | 11.49 |
| 9 | Cipla | 2.98 | 3.15 | 5.62 |
| 10 | Lupin | 2.35 | 2.59 | 10.17 |
| 11 | Aspen | 2.33 | 2.42 | 4.14 |
| 12 | Celltrion | 1.67 | 2.41 | 43.78 |
| 13 | Gedeon Richter | 2.14 | 2.13 | -0.5 |
| 14 | Krka | 1.99 | 1.98 | -0.24 |
| 15 | Stada | 1.65 | 1.72 | 3.95 |
| 16 | Amneal | 1.47 | 1.68 | 14.52 |
| 17 | Towa Pharmaceutical | 1.67 | 1.6 | -4.14 |
| 18 | Zydus | 1.28 | 1.57 | 23.13 |
| 19 | Glenmark | 1.41 | 1.53 | 8.89 |
| 20 | Alkem | 1.51 | 1.49 | -1.61 |
Note: Columns 1 and 2 represent ranks and companies, while Columns 3, 4, and 5 showcase the total generic revenue of 2023, the total revenue of 2024, and the percentage change.
20. Alkem
Generic Segment Revenue: $1.49B
Founded Year: 1973
Market Cap: $7.38B
Total Employees: ~21000
Headquarters: Maharasthra, India
Stock Exchange: NSE
- Alkem Laboratories is a leading Indian pharmaceutical developer with a significant global generics, formulations, and nutraceuticals portfolio; key products include Livoerb, Omee MPS, and Alkem Dexa
- Reported $1.49B in 2024 generic revenue, a decrease of 1.6% from 2023, attributed to subdued product sales
- In October 2024, received ANDA approval for Topiramate Oral Solution for epilepsy treatment
19. Glenmark
Generic Segment Revenue: $1.53B
Founded Year: 1977
Market Cap: $6.17B
Total Employees: 15,800
Headquarters: Maharasthra, India
Stock Exchange: NSE
- Glenmark Pharmaceuticals is an Indian company specializing in branded generics, specialty medicines, and OTC products, with flagship brands such as Glempa, Apremilast, and Sacu VTM
- Achieved $1.53B in 2024 generic segment revenue, reflecting an 8.9% increase driven by higher sales volumes
- Launched Lacosamide oral solution (Vimpat) in the U.S. market in December 2024
18. Zydus
Generic Segment Revenue: $1.57B
Founded Year: 1952
Market Cap: $11.21B
Total Employees: 27,000
Headquarters: Ahmedabad, India
Stock Exchange: NSE
- Zydus is an Indian multinational firm engaged in formulations, APIs, and animal health products; prominent generic offerings include Acamprosate calcium DR tablets and Acetazolamide ER capsules
- Posted $1.57B in generic revenue for 2024, a 23.1% year-over-year rise due to increased sales activity
- ZyVac TCV received WHO prequalification, enabling U.N. procurement for typhoid prevention in October 2024
17. Towa Pharmaceutical
Generic Segment Revenue: $1.6B
Founded Year: 1951
Market Cap: $1.01B
Total Employees: 4,788
Headquarters: Osaka, Japan
Stock Exchange: TYO
- Towa Pharmaceutical is a Japanese research-based company focused on manufacturing and marketing generic formulations such as Ambroxol and Ropinirole
- Recorded $1.60B in 2024 generic revenue, representing a 4.1% decline due to market headwinds
- Towa was granted approval for six generic ingredients and ten new items in August 2024
16. Amneal
Generic Segment Revenue: $1.68B
Founded Year: 2002
Market Cap: $3.25B
Total Employees: 8,300
Headquarters: New Jersey, United States
Stock Exchange: NASDAQ
- Amneal is an American multinational producing generics, injectables, biosimilars, and specialty drugs, with leading products like Abiraterone Acetate and Chloroquine Phosphate
- Reported $1.68B in 2024 generic revenues, up 14.5% from the previous year based on robust generic launches
- Entered into a long-acting injectable development deal with Kashiv in March 2024
15. STADA Arzneimittel
Generic Segment Revenue: $1.72B
Founded Year: 1895
Market Cap: N/A
Total Employees: 11,500
Headquarters: Bad Vilbel, Germany
Stock Exchange: N/A
- STADA is a German company with portfolios in consumer healthcare, generics, and specialty medicines, including Tilidine, Atorvastatin, and Pantoprazole
- Saw $1.72B in generic segment revenue in 2024, growing 3.9% year-over-year through product and market expansion
- Acquired FITO from LEO Pharma in August 2024 to broaden its business
14. KRKA
Generic Segment Revenue: $1.98B
Founded Year: 1954
Market Cap: $7.61B
Total Employees: 13,000
Headquarters: Novo Mesto, Slovenia
Stock Exchange: WSE
- KRKA is a Slovenian manufacturer offering prescription and non-prescription generics, and animal health products; notable products are Rivaroxia and Zomiren
- Generated $1.98B in 2024 generic revenue, down 0.2%, reflecting currency-induced declines despite organic growth
- Formed a joint venture with Laurus Labs in India (January 2024) to expand its regional footprint
13. Gedeon Richter
Generic Segment Revenue: $2.13B
Founded Year: 1901
Market Cap: N/A
Total Employees: ~10,900
Headquarters: Budapest, Hungary
Stock Exchange: FRA
- Gedeon Richter is a Hungarian pharmaceutical specialist in innovation, generics, and OTCs for women’s health and the central nervous system; key generics include Postinor and Cerazette.
- Reported a 2024 generic revenue of $2.13B, a 0.5% decrease attributed to weak sales
- Established a collaboration with Bio-Thera for commercializing the Stelara biosimilar (BAT2206) in October 2024
12. Celltrion
Generic Segment Revenue: $2.41B
Founded Year: 2002
Market Cap: $28.65B
Total Employees: ~2,700
Headquarters: Incheon, South Korea
Stock Exchange: KRX
- Celltrion Healthcare is a South Korean biopharma leader developing generic and biosimilar drugs, with a portfolio featuring Inflectra, Truxima, and Herzuma
- Achieved $2.41B in generic revenue for 2024, up 43.8% on strong biosimilar sales worldwide
- In December 2024, Health Canada approved Omlyclo, a Xolair biosimilar, expanding Celltrion’s North American presence
11. Aspen
Generic Segment Revenue: $2.42B
Founded Year: 1850
Market Cap: $2.48B
Total Employees: ~9,100
Headquarters: Durban, South Africa
Stock Exchange: JSE
- Aspen is a South African group manufacturing post-patent brands and generics, including sterile injections and APIs, for hospital and consumer segments
- Delivered $2.42B in generic segment revenue during 2024, up 4.1% year-over-year on organic growth
- Teamed with PinkDrive in October 2024 to promote cancer screening and awareness
10. Lupin
Generic Segment Revenue: $2.59B
Founded Year: 1968
Market Cap: $9.84B
Total Employees: ~24,000
Headquarters: Mumbai, India
Stock Exchange: NSE
- Lupin is an Indian multinational developing branded and generic pharmaceuticals, APIs, and biosimilars; key products include Ab-Next, Abdowell, and Adhero
- Registered $2.59B in generic revenue for 2024, an increase of 10.2% driven by U.S. market gains
- Received tentative U.S. FDA approval for Raltegravir tablets in November 2024
09. Cipla
Generic Segment Revenue: $3.15B
Founded Year: 1935
Market Cap: $13.63B
Total Employees: ~30,300
Headquarters: Mumbai, India
Stock Exchange: NSE
- Cipla is a global Indian pharmaceuticals giant offering branded medications, generics, and APIs, especially for respiratory and chronic therapies; known for Foracort and Budecort
- Reported $3.15B in 2024 generic segment revenue, a 5.6% increase attributed to chronic portfolio growth
- Signed a non-exclusive licensing agreement with Takeda in June 2024 to commercialize Vonoprazan in India
08. Dr. Reddy’s
Generic Segment Revenue: $3.51B
Founded Year: 1984
Market Cap: $11.61B
Total Employees: ~27,800
Headquarters: Hyderabad, India
Stock Exchange: NSE
- Dr. Reddy’s is an Indian multinational with business lines in global generics and pharmaceutical services; highlights include Lenalidomide, Treprostinil, and Regadenoson generics
- Recorded $3.51B in generic revenue for 2024, a rise of 11.5% on strong international sales
- Partnered with Senores Pharmaceuticals to launch Ivermectin (Stromectol) in the U.S. in November 2024
07. Teva Pharmaceuticals
Generic Segment Revenue: $3.59B
Founded Year: 1944
Market Cap: $23.26B
Total Employees: 37,000
Headquarters: Tel Aviv, Israel
Stock Exchange: TLV
- Teva Pharmaceuticals is an Israeli firm specializing in generics, specialty medicines, and biosimilars; portfolio features Acitretin, Acyclovir, and Capecitabine
- Totaled $3.59B in generic revenue for 2024, up 14.7% year-over-year due to new product launches and high demand
- Strengthened its oncology biosimilars partnership with mAbxience in October 2024
06. Aurobindo Pharma
Generic Segment Revenue: $3.61B
Founded Year: 1986
Market Cap: $7.08B
Total Employees: ~27,700
Headquarters: Hyderabad, India
Stock Exchange: NSE
- Aurobindo Pharma is an India-based global generics and specialty pharma leader, with key generics like Zovirax and Xanax XR
- Announced $3.61B in 2024 generic revenues, a 10.9% increase, primarily from high demand
- Subsidiary CuraTeQ Biologics received UK MHRA approval for Bevqolva biosimilar in December 2024
05. Fresenius Kabi
Generic Segment Revenue: $3.99B
Founded Year: 1999
Market Cap: $30.45B
Total Employees: ~176,200
Headquarters: Bad Homburg, Germany
Stock Exchange: ETR
- Fresenius Kabi is a subsidiary of Germany-based multinational healthcare company Fresenius SE & Co. KGaA. The company develops and distributes essential medicines and technologies for the treatment of chronic conditions
- Fresenius Kabi’s generic portfolio comprises products such as Adalimumab, Pegfilgrastim, Tocilizumab, and Ustekinumab, among others. Reported 2024 generic segment revenue of $3.99B, a 5.5% decline, mainly due to low biosimilar sales
- Introduced a generic Epinephrine 1mg/1mL in the U.S. in December 2024
04. Viatris
Generic Segment Revenue: $5.49B
Founded Year: 2020
Market Cap: $11.82B
Total Employees: 32,000
Headquarters: Pennsylvania, United States
Stock Exchange: NASDAQ
- Viatris is an American developer of branded, generics, and complex medicines across multiple therapeutic areas; generics portfolio includes Abiraterone and Acamprosate
- Reported $5.49B in 2024 generic revenue, a decrease of 1.7% linked to lower international sales
- Released positive Phase III data for Effexor in Japanese adults with GAD in October 2024
03. Fosun Pharma
Generic Segment Revenue: $5.6B
Founded Year: 1978
Market Cap: $10.69B
Total Employees: ~40,600
Headquarters: Shanghai, China
Stock Exchange: SHA
- Shanghai Fosun Pharmaceutical (Group), also known as Fosun Pharma, is a Chinese multinational with prescription and generic products, medical devices, and healthcare services; generic offerings include Han Da Yuan and Han Qu You
- Generated $5.6B in generic revenue for 2024, down 3.7% year-over-year due to moderate sales
- Gained NMPA approval for Daxxify toxin product in China in September 2024
02. Sun Pharma
Generic Segment Revenue: $6.26B
Founded Year: 1983
Market Cap: $44.28B
Total Employees: 43,000
Headquarters: Mumbai, India
Stock Exchange: NSE
- Sun Pharma is India’s largest pharmaceutical company, focusing on branded and generic medicines as well as APIs; operates a portfolio including Absenz and Betavert
- Achieved $6.26B in generic segment revenue, up 7.5%, reflecting robust generic demand in 2024
- In June 2024, inked a patent-licensing deal with Takeda for the GI drug Voltapraz (Vonoprazan) in India
01. Sandoz
Generic Segment Revenue: $10.35B
Founded Year: 1886
Market Cap: $26.2B
Total Employees: 23,000
Headquarters: Basel, Switzerland
Stock Exchange: SWX
- Sandoz is a Swiss industry leader in generics and biosimilars, with a global reach spanning over 100 countries and products like Erelzi and Hyrimoz
- Generated $10.35B in 2024 generic revenue, a 7.4% increase from 2023 led by global biosimilars expansion
- Secured European Commission approval for Afqlir (aflibercept), reinforcing its biosimilar leadership.
Sources:
- Annual reports
- SEC Filings
- Press releases
- Company websites
Currency Conversion: Oanda (£1 – $1.25, €1 – $1.04, kr.1 – 0.13, CHF 1 – 1.1, ₩1– 0.00068,
HUF1 – 0.00253, ZAR1 – 0.0533, ¥1 – 0.13698; Dec 31, 2024)
Related Posts: Top 20 Generic Pharma Companies of 2024
